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Abstract
Background: Genital chlamydia is the most commonly notified sexually transmissible infection (STI) in Australia
and worldwide and can have serious reproductive health outcomes. Partner notification, testing and treatment are
important facets of chlamydia control. Traditional methods of partner notification are not reaching enough
partners to effectively control transmission of chlamydia. Patient-delivered partner therapy (PDPT) has been shown
to improve the treatment of sexual partners. In Australia, General Practitioners (GPs) are responsible for the bulk of
chlamydia testing, diagnosis, treatment and follow up. This study aimed to determine the views and practices of
Australian general practitioners (GPs) in relation to partner notification and PDPT for chlamydia and explored GPs’
perceptions of their patients’ barriers to notifying partners of a chlamydia diagnosis.
Methods: In-depth, semi-structured telephone interviews were conducted with 40 general practitioners (GPs) from
rural, regional and urban Australia from November 2006 to March 2007. Topics covered: GPs’ current practice and
views about partner notification, perceived barriers and useful supports, previous use of and views regarding PDPT.
Transcripts were imported into NVivo7 and subjected to thematic analysis. Data saturation was reached after 32
interviews had been completed.
Results: Perceived barriers to patients telling partners (patient referral) included: stigma; age and cultural
background; casual or long-term relationship, ongoing relationship or not. Barriers to GPs undertaking partner
notification (provider referral) included: lack of time and staff; lack of contact details; uncertainty about the legality
of contacting partners and whether this constitutes breach of patient confidentiality; and feeling both personally
uncomfortable and inadequately trained to contact someone who is not their patient. GPs were divided on the
use of PDPT - many felt concerned that it is not best clinical practice but many also felt that it is better than
nothing.
GPs identified the following factors which they considered would facilitate partner notification: clear clinical guide-
lines; a legal framework around partner notification; a formal chlamydia screening program; financial incentives;
education and practical support for health professionals, and raising awareness of chlamydia in the community, in
particular amongst young people.
Conclusions: GPs reported some partners do not seek medical treatment even after they are notified of being a
sexual contact of a patient with chlamydia. More routine use of PDPT may help address this issue however GPs in
this study had negative attitudes to the use of PDPT. Appropriate guidelines and legislation may make the use of
PDPT more acceptable to Australian GPs.
* Correspondence: npavlin@ozisp.com.au
1Department of General Practice, The University of Melbourne, 200 Berkley
Street, Carlton, Victoria, Australia
Full list of author information is available at the end of the article
Pavlin et al. BMC Infectious Diseases 2010, 10:274
http://www.biomedcentral.com/1471-2334/10/274
© 2010 Pavlin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Genital chlamydia (Chlamydia trachomatis)i n f e c t i o ni s
the most commonly notified sexually transmissible
infection (STI) in Australia and one of the most preva-
lent worldwide [1]. Chlamydial infections can have ser-
ious reproductive health outcomes, particularly for
women, and can result in tubal infertility, and ectopic
pregnancy [2]. General practitioners (GPs) in Australia
are ideally placed to conduct widespread chlamydia
screening as nearly 90% of Australian women aged 15-
24 years of age, the key risk group [2] visit a GP at least
once each year [3]. As such GPs have been the focus for
Australia’s chlamydia screening efforts and are the pro-
viders most likely to be treating chlamydia. Australia’s
treatment guidelines for chlamydia include antibiotic
treatment for the index case and their known partners
and a repeat test for re-infection 3 months after treat-
ment [4].
A cornerstone in the management of treatable STIs is
the testing and treatment of sexual partners [5]. Effec-
tive partner management potentially prevents infection
and its sequelae in partners and reduces the risk of re-
infection in the index case.
There is concern that traditional methods of partner
notification, such as patient or provider referral, are not
reaching enough partners to effectively control the
transmission of chlamydia [6-8]. Patient referral involves
the person diagnosed with the STI contacting their part-
ners themselves. Provider referral has traditionally
meant public health staff, who are trained in partner
notification, contacting partners on behalf of the patient.
In recent years provider referral has also been used to
describe health care providers - both medical and nur-
sing - performing this function. Minimal evidence exists
of the efficacy of this type of provider referral. There is
limited availability of trained public health staff to per-
form partner notification in Australia and in practice
only patients themselves and in some cases their doctors
or nurses are active in partner notification for chlamy-
dia. Various approaches have been tried around the
world to improve notification and treatment of sexual
partners. These include point of care counselling, inter-
net and SMS based partner notification and patient-
delivered partner therapy (PDPT) [5-7]. This involves
the patient delivering antibiotics (e.g. single-dose azi-
thromycin) to their sexual partner/s, without the partner
attending a consultation with a health professional. Stu-
dies have shown PDPT to be as effective as, and in
some cases more effective, than patient referral in both
the proportion of sexual partners treated, and in redu-
cing re-infection rates in index women [9-15]. PDPT is
currently used in Sweden and parts of the USA [8,15],
and has been recommended as an option for the
management of chlamydia in draft guidance from the U.
K. National Institute for Health and Clinical Excellence
[15]. PDPT provides flexibility for treatment of partners
who are unwilling or unable to attend a consultation
with a health professional [6]. However, PDPT is a con-
troversial practice as it involves a health professional
providing medication for an individual that they have
not met, nor clinically evaluated [15].
In Australia, research suggests GPs want guidance and
support for partner notification and there is currently
no specific legislation or guidelines supporting the use
of PDPT [16]. Aside from legal considerations, clinicians
contemplating PDPT also face potential medico-legal
and ethical issues stemming from the treatment of indi-
viduals who are not “their” patients. Few published data
exist on clinicians’ use of and views on PDPT from
countries where it is not specifically supported nor seen
as normal clinical practice. This study aimed to deter-
mine the views and practices of Australian general prac-
titioners (GPs) on partner notification, particularly in
relation to PDPT and explored GPs’ perceptions of their
patients’ barriers to notifying partners of a chlamydia
diagnosis.
Methods
Ethics approval was obtained from University of Mel-
bourne Human Research Ethics Committee. All partici-
pants gave informed consent. In-depth, semi-structured
telephone interviews were conducted with 40 GPs from
November 2006 to March 2007.
GPs from Queensland, Victoria and the ACT (n =
9826 ) were initially identified by postcode from the
AMPCo database [17]. GPs from Queensland and Vic-
t o r i aw e r et h e nd i v i d e di n t or u r a la n du r b a na r e a s .A
statistician randomised each group. GPs known to work
in Indigenous Health were also approached via tele-
phone listings in the White Pages Telephone Directory.
GPs with experience in working with Indigenous Aus-
tralians were oversampled to ensure their views were
represented in the study.
To be eligible to participate GPs must have diagnosed
at least one case of chlamydia in the past year.
Each week 15 rural and 15 urban GPs from Victoria
and Queensland and 7 from the Australian Capital Ter-
ritory (ACT) were contacted by mail or fax and fol-
lowed up with a phone call until 40 GPs had been
interviewed. Over an 11 week period there were 7 mail
outs; 59 letters sent to rural Victoria; 59 to urban Vic-
toria; 65 to rural Queensland; 60 to urban Queensland
and 43 letters sent to GPs in the ACT. Forty letters
were sent to GPs currently working in Indigenous
health in rural Victoria, urban Victoria and rural
Queensland.
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rent practice and views about partner notification, bar-
r i e r st h e ye x p e r i e n c ea n ds u p p o r t st h e yn e e dt om o r e
effectively implement the partner notification process
for patients with chlamydia. Specific questions were
asked about previous use of and views regarding PDPT.
The interview schedule was piloted with two GPs and
amended following review by authors RP and NP. NP
conducted all interviews; she is a practicing GP and was
able to relate to the participants’ concerns and environ-
ment, and to probe their responses appropriately. NP
was supervised by RP who has extensive experience con-
ducting interviews on sensitive topics and acknowledged
skills in qualitative research. RP regularly listened to
interview recordings and provided feedback to NP.
Interviews took 30-40 minutes, were audio-taped,
transcribed, imported into NVivo7 as a Word document
and subjected to thematic analysis. [18]. To avoid bias,
both NP and RP read all transcripts and developed a
coding framework. Emerging themes were reviewed as
t h ea n a l y s i sp r o g r e s s e d ,a n dm a d eu s eo ft h ed i f f e r e n t
perspectives of NP (GP researcher) and RP (sociologist).
Data saturation was reached when no new themes
emerged after the initial 32 interviews were analysed,
although a further 8 were completed and analysed.
Results
The 40 GPs interviewed work predominately in private
general practice although as mentioned previously doc-
tors working in Aboriginal Medical Services were delib-
erately oversampled. Table 1 describes the
demographics of the GPs interviewed for this study.
Communication difficulties (in terms of English lan-
guage skills) were evident in five interviews. Twenty-
three interviewees worked full-time in General Practice
(defined as >30 hours per week) and 17 worked part-
time ( < 30 hours per week). Twenty-five GPs reported
no experience with Indigenous patients, five reported
some experience with Indigenous patients and ten had
very significant experience with Indigenous patients. All
denied having a particular interest in sexual health.
Current methods of partner notification
Various methods of partner notification were used by
the GPs. A majority viewed partner notification as the
patient’s responsibility (patient referral), a finding con-
sistent with other Australian studies [16,19,20]. Provider
referral was undertaken by a small number of GPs.
Many GPs expressed confusion about the ‘correct’ pro-
tocol for partner notification, and uncertainty about the
roles and responsibilities of themselves, their patients
and the public health authorities.
...is it the GP’s role to contact all their partners, or is it the
DHS [Department of Human Services], or who? (Dr RE 185)
Barriers to partner notification and treatment
Perceived barriers to patients telling partners included:
the stigma of having an STI; patient factors such as age
and cultural background; and relationship factors such
as whether it is a casual or long-term relationship, and
whether the relationship is ongoing or has ended.
...in terms of getting people to make sure that other
relationships are notified... I think the conflict there is
that for young people sometimes it’sv e r yt r a u m a t i ct o-
to disconnect from an intense and intimate relationship.
And having completed the disconnection, I don’tt h i n k
they actually want to revisit it on any level. (Dr DC 246)
And so... they might’ve had a number of boyfriends
over a reasonably short period of time. And you sort of
try to say, well, it could be any of those guys, so maybe
you should actually inform them all. But that’sv e r y
threatening... and I’m sure they don’t do it. (Dr KN 256)
Table 1 Demographics of GPs interviewed
Total GPs
Interviewed
Private General
Practice
Aboriginal Medical
Service
University
Health Service
Australian
Defence Force
Occupational
Medicine
After Hours
Deputising Service
n = 40 26 8 2 2 1 1
Total GPs
Interviewed
Australian Capital
Territory
Victoria Queensland
n = 40 4 24 12
Total GPs
Interviewed
Urban Areas Rural and Regional
Areas
n = 40 21 19
Total GPs
Interviewed
Female Male
n = 40 19 21
Total GPs
Interviewed
Australian Trained
Medical Graduates
International Medical
Graduates
n = 40 29 11
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notification (provider referral) included: lack of time and
staff to undertake the work; logistical difficulties such as
lack of contact details; uncertainty about the legality of
contacting partners and whether this constitutes breach
of patient confidentiality; and feeling both personally
uncomfortable and inadequately trained to contact
someone who is not their patient.
Well, resource number one, time. Number two, which
staff member would do it, so you’d have to allocate a
person to it, and that is all work for free. (Dr DL ATSI
348)
It h i n ki t ’s, you know, hard to be on the end of the
phone and going, “Hello, you don’tk n o wm ef r o mab a r
of soap but I think we need to test you for chlamydia”.
You know that conversation is always going to be a hard
one and I think that is a big barrier. (Dr GY 371)
Many GPs felt that a particular barrier to effective
treatment of partners is that, even once notification has
occurred, many partners are unwilling or unable to
attend a consultation with a health professional.
I guess the main barrier we would see is that people
won’t come in. We do have an urgent recall as I say for
more than six months, twelve months and they just
won’t come in, so whether they’ve got a suspicion of what
it is, or they just haven’t sort of formed a rapport with
the practice, um, that’d be our main thing... (Dr EC
ATSI 306)
Probably the other thing is gender related because
males are reluctant to come to the doctors in general,
and the partners - the patients who are screening are
mostly females, and males don’t come to the doctor, so
probably that’s a barrier, the gender itself.( Dr EP 241)
The - you know, the amount of trouble you have to go
to contact some people is - is astounding. And even when
you get on to them and tell them that they have to come,
they still don’t come. (Dr KN 512)
Facilitators for better partner notification and treatment
GPs identified the following factors which they consid-
ered would facilitate partner notification: clear clinical
guidelines; a legal framework around partner notifica-
tion; a formal chlamydia screening program; financial
incentives; education and practical support for health
professionals, and raising awareness of chlamydia in the
community, in particular amongst young people.
I think it would be...more a clear system change. So,
some sort of... clear guidelines for a GP to follow, and,
you know, with the - the legal or government backup
that we’re sort of obliged to do this thing. And, you
know, therefore involve the patient and everything in a
way that’sab i tl e s sa m b i g u o u st h a ni ti sn o w .( D rE A
ATSI 721)
I mean the public awareness of it - if there was a
national campaign which would run, would obviously be
a lot better. So that might be...helpful I guess in some
respects. But the awareness of it would be increased, so
that... perhaps people would then have a better baseline
knowledge in terms of...contact tracing...and the impor-
tance of it, and ah, it’s necessary - necessary nature of it.
(Dr TM 447)
Views on PDPT
Slightly fewer than half of the GPs expressed positive
views about PDPT and slightly more than half expressed
negative views about PDPT. Of those who expressed
negative views it appeared that a small minority felt
strongly against PDPT and the remainder had more
moderate concerns. A small number of the interviewed
GPs did not have any particular views on PDPT.
Positive attitudes to PDPT
Those with positive attitudes towards PDPT mostly
expressed the viewpoint that while the ideal situation
would be to clinically evaluate the partner, PDPT is pre-
ferable to no treatment at all. They considered that the
benefits outweighed the risks.
... it’s probably best to see them anyway... I mean, for
counselling. But if you suspect that they will never come
back, it’s probably a better result for population health
rather than not give anything. (Dr EP 190)
But if you’ve got a situation where that’sy o u ro n l y
option for treatment them, then ah, it’s better than noth-
ing, I would say.[ I n ]the scheme of things the ideal care
would be to have them come in, and talk to them about
all their sexual stuff, and make sure there are no other
things that you need to treat or deal with. But if you’ve
got a partner who’s just not going to come in, and the
only way you’re going to get them treated is if the girl-
friend takes - takes them home and gives them [the med-
ication] - I mean, you know. It’s probably better than not
treating them at all. (DR HR ATSI 330)
Some GPs considered PDPT, including the fact that
they were not actually testing the partner for chlamydia,
to be acceptable as usual practice would be to treat
such patients empirically due to known exposure to a
case.
In this scenario it’s easier because we know that he has
to be treated, so - and we know that - and you would
treat him anyway. We wouldn’td os w a b s .W ew o u l d
treat him anyway because he’s-h e ’s a possible contact.
So I think it’s all right to give a script without seeing
someone if - if that’s - would be the end result anyway.
(Dr EP 183)
Several GPs considered that PDPT had evidence-based
benefits.
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Page 4 of 7I’ve actually - um, about a year ago I looked up sort of
one of these evidence-based, ah, web pages and I saw
that there is some evidence to say that that is a good
idea, and we would commonly do it. (Dr EC ATSI 277)
Negative attitudes to PDPT
Clinical, medicolegal and ethical concerns regarding the
use of PDPT were expressed by some GPs.
Clinical concerns
The most commonly expressed concern was that PDPT
did not represent best clinical practice. Specific concerns
included: the lack of opportunity to undertake a com-
plete history and clinical examination, in particular to
assess for contraindications to medication such as aller-
gies or drug-drug interactions; lack of diagnostic testing
before, and follow-up testing after treatment; lack of
investigation for complications of chlamydial infection
or concurrent STIs; missed opportunity for information
sharing between the health professional and the partner;
and lack of further tracing of the partner’s other sexual
contacts.
Well, I don’t think that would be looked at as a rea-
sonable option by the College [Royal Australian College
of General Practitioners] or standards or peers. (Dr EG
288)
There are medical issues with that - can you be sure of
what their allergies are? Can you be sure that they are
not pregnant or not taking some sort of other medication
that will interfere with the normal treatment? Definitely
it deprives them of a follow up, in that most people - all
people with chlamydia should be tested two weeks later
to confirm clearance of the infection. That isn’tg o i n gt o
happen if you prescribe by proxy. The other last thing
that is of significance is that if somebody has chlamydia
that greatly enhances their risk of acquiring another
sexually transmitted disease at the same time. Treating
the chlamydia alone is arguably inadequate treatment
for the other partner. (Dr BK 192)
Many GPs were concerned that PDPT might not be
effective. A particular concern was whether the doctor
could be sure that the partner has been notified and
given the script, and whether the script is filled and the
medication goes to the person it was intended for.
Medicolegal and ethical concerns
Some GPs had specific concerns about the medicolegal
implications of PDPT.
And can you imagine standing in the Coroner’s Court
saying, “Yeah, well, I hadn’t even seen them, hadn’t even
met them before, and um, you know, I wrote a script for
them, or wrote a script for my patient knowing full well
that they were going to give it to somebody else.” I mean,
it’s-i t ’s illegal. (Dr MS 227)
Others were concerned that patients may use the
medication to treat their partners without the partner’s
full understanding, and that this would not meet the
ethical and legal requirement of informed consent for
treatment.
I think the medico-legal issue there is probably the big-
gest one. If they’re on some kind of concurrent medica-
tion or have an allergy - they need to know why they’re
taking it. I could foresee a scenario where it gets slipped
into their, um, Vegemite toast in the morning...(Dr TM
365)
And I think it’s probably important to make sure that
the information they’re getting is the correct information,
‘cause the partner may [say], you know, “Ij u s tn e e dy o u
to take this ‘cause I’ve got thrush and we need to treat
the thrush,” and they go, “Oh yeah, okay, that’s fine.” (Dr
GY 344)
Discussion
This is one of the first qualitative studies to investigate
Australian GPs’ attitudes towards PDPT as an approach
to treating partners of patients with chlamydia. Both
positive and negative views were expressed by GPs. A
barrier to effective management of partners as identified
by many of the GPs is that some partners are unwilling
or unable to seek timely medical treatment even after
they are notified of being a sexual contact of a patient
with chlamydia. This finding is significant, as it identifies
a need that could be met by the use of PDPT, which
provides a flexible alternative for treatment of partners
who may otherwise be left untreated. Guidelines and
legislation are required in Australia to support GPs in
using PDPT where appropriate.
Through the interviews with the GPs, it became clear
that there is no uniform approach to partner notification
for chlamydia in Australia, a finding reported elsewhere
[16,19]. While patient referral was the most commonly
reported method used, provider referral was used by a
smaller number of GPs. GPs felt they would be better
able to facilitate partner notification if they received
clarification about best practice, and about the roles and
responsibilities of patients, GPs and the public health
authorities. Education, tools and practical support for
GPs were also identified as possible facilitators for part-
ner notification in this study, and in other recent Aus-
tralian studies [20,21]. Online services that allow
patients to email or text message partners have also
shown promise and could assist both GPs and patients
with partner notification [6,21].
GPs in this study expressed negative views about
PDPT. This is in contrast to similar surveys conducted
in the U.K. and the U.S., in which a majority of doctors
interviewed expressed positive views about PDPT, and/
or a willingness to use it [6,8,22]. This difference may
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samples - in many of the overseas studies, the doctors
sampled included gynaecologists, genitourinary physi-
cians, or doctors with a particular interest in family
planning and sexual health. In addition, PDPT is legal in
some jurisdictions within the U.S. [23], and its use is
encouraged, so doctors there are likely to be more com-
fortable about using PDPT.
Another important factor, which may explain this dif-
ference, is the context in which the use of PDPT is pro-
posed. The concern most commonly expressed about
PDPT by GPs in this study was that PDPT did not
represent best practice. The GPs were clearly concerned
about providing medication for someone whom they
had never met, let alone clinically evaluated with a thor-
ough history and examination. This is understandable as
PDPT does represent a significant departure from the
traditional doctor-patient relationship, particularly in a
setting such as Australia with a tradition of strict regula-
tion of prescribed medications. However, PDPT as it is
used overseas is not intended to replace best practice,
but to be available as an option to treat partners who
would otherwise not be treated at all. For example, Cali-
fornian guidelines for the use of PDPT state that its use
should be restricted to “those with partners who are
unable or unlikely to seek timely clinical services“ [24].
Similarly, in this study, those GPs who supported PDPT
recognised that it was not best practice, but that it
could be a useful compromise in situations where the
alternative would be no treatment at all.
In addition to clarification about the situations in
which PDPT is appropriate, other practical concerns
e x p r e s s e db yt h eG P si nt h i ss t u d yw o u l da l s on e e dt o
be addressed before it is seen as a legitimate treatment
option. Many GPs felt that PDPT may not be safe, parti-
cularly because the patient would not be assessed for
the possibility of allergic reactions to the medication.
However, azithromycin, the drug usually prescribed in
PDPT, is generally a well-tolerated and safe antibiotic,
with a low incidence of allergic reactions [15]. Although
a number of GPs considered that PDPT may not be
very effective, some studies have found that it is equally
or more effective than patient referral partner notifica-
tion [9-15], the method currently employed by the
majority of GPs in Australia.
GPs were concerned that PDPT may result in incom-
plete care for the partner, since they are not evaluated
for complications of infection (such as pelvic inflamma-
tory disease in women), or for concurrent STIs. While
the likelihood of such complications and concurrent
infections depends on the population of interest, a
recent Australian study has concluded that the incidence
of these complications and concurrent infections in het-
erosexual partners is low enough to recommend the use
of PDPT [25]. Further studies should be done to con-
firm these findings, and to help clarify the populations
in which PDPT could be safely used.
Another concern was the lack of opportunity to trace
the partner’s additional sexual contacts. A recent audit
conducted in Scotland found that the use of PDPT
meant that 22-28% fewer additional cases of chlamydia
were found than when partners were clinically evaluated
and secondary sexual contacts traced [26].
It should be noted that if the alternative to PDPT is
not informing of partners at all, this also prevents eva-
luation of the sexual partner for complications and con-
current infections, and secondary contact tracing.
Therefore, some may consider that it is preferable to
use PDPT in these settings, as at least it has the benefit
of empirically treating the chlamydial infection of the
sexual partner.
A strength of this study is the inclusion of GPs across
a broad range of backgrounds and locations across Aus-
tralia. As this was a preliminary study, and the inter-
views had a broad scope, some issues identified would
benefit from further in-depth study. Future research on
the attitudes of GPs towards PDPT, with more probing
questions and scenario-based discussion, would allow
for deeper understanding of this complex issue. In addi-
tion, an important area for further research would be
the views of patients themselves on the use of PDPT [6].
Conclusions
This small qualitative study of Australian GPs found
that at present more GPs have negative rather than
positive views about PDPT for the treatment of sexual
partners of patients with chlamydia. Many of the con-
cerns expressed by the GPs are likely to be ameliorated
by the provision of further information about the appro-
priate use of PDPT and its safety and effectiveness. Ulti-
mately, guidelines, decision support tools and legislative
changes that specifically support PDPT are needed,
before practitioners feel comfortable with the use of
PDPT.
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